Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market

by | Apr 6, 2026 | General

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares are down during Monday’s premarket session.

The company announced plans to acquire Soleno Therapeutics Inc. (NASDAQ:SLNO) for $53.00 per share in cash, totaling approximately $2.9 billion.

The company plans to finance the transaction using cash on hand along with pre-payable debt.

As of December 31, 2025, Neurocrine reported cash, cash equivalents, and marketable securities of approximately $2.54 billion.

Strategic Rationale

The acquisition aims to expand Neurocrine’s portfolio with Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, which could significantly enhance its revenue potential as the company strengthens its position in the endocrinology and rare disease markets. The deal is expected to close within 90 days.

The acquisition of Soleno Therapeutics is a strategic move for Neurocrine, as it adds a high-growth product to its lineup, potentially driving long-term revenue growth.

Vykat XR has already shown strong early adoption, generating $190 million in revenue in 2025, including $92 million in the fourth quarter.

Vykat XR Launch Performance

In March 2025, the U.S. Food and Drug Administration (FDA) approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).

In August 2025, a short report from Scorpion Capital criticized Vykat XR as overpriced and potentially unsafe for PWS children.

Neurocrine Technical Analysis Signals Mixed Momentum

At $131.00, the stock is trading 4.5% below its 200-day simple moving average (SMA), indicating a bearish trend in the long term. The absence of recent moving averages suggests a lack of clear short-term momentum, which traders should monitor closely.

The stock has performed well over the past year, with a 12-month return of 41.13%, reflecting strong investor interest and growth potential. Currently, it is positioned between its 52-week high of $160.18 and low of $84.23, suggesting that it has room to recover if market conditions improve.

  • Key Resistance: $135.00 — This level may act as a barrier for upward price movement.
  • Key Support: $122.50 — A drop below this level could indicate further selling pressure.

Benzinga Edge Rankings Highlight Neurocrine Growth Profile

Below is the Benzinga Edge scorecard for Neurocrine Biosciences, highlighting its strengths and weaknesses compared to the broader market:

  • Value: 59.44 — Indicates moderate valuation relative to peers.
  • Growth: 88.39 — Suggests strong growth potential.
  • Quality: 62.19 — Reflects a decent balance sheet.
  • Momentum: 52.61 — Indicates neutral momentum.

The Verdict: Neurocrine Biosciences’ Benzinga Edge signal reveals a growth-heavy profile, bolstered by strong growth potential and a solid quality ranking.

However, the moderate value score suggests that the stock may be trading at a premium compared to its peers.

ETF Exposure And Market Reaction

  • Tema Neuroscience and Mental Health ETF (NASDAQ:MNTL): 5.02% Weight
  • SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI): 2.59% Weight
  • iShares Morningstar Small-Cap Growth ETF (NYSE:ISCG): 0.48% Weight

Price Action: Neurocrine Biosciences shares were down 2.74% at $128.00 during premarket trading on Monday, according to Benzinga Pro data. Soleno Therapeutics shares were up 32.84% at $52.46.

Image via Shutterstock